It is known that these genes are often silenced by DNA methylation in basal-like breast cancers16,17, including triple-negative breast cancer (TNBC, negative for ER/PR/HER2 expression) that represents one of the most aggressive types of human cancer and is highly resistant to virtually all targeted therapies and anti-estrogen treatments. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.